World's Best Scientists 2026 revealed!
Award Badge
Medicine
Australia
2023

D-Index & Metrics

Medicine

D-Index
128
Citations
70233
World Ranking
2681
National Ranking
77

Research.com Recognitions

  • 2023 - Research.com Medicine in Australia Leader Award

Overview

John F. Seymour is affiliated with the Peter MacCallum Cancer Centre in Australia. Their research primarily spans the field of Medicine, with a strong focus on several key subfields including Genetics, Pathology and Forensic Medicine, Oncology, Hematology, and Immunology.

The main topics covered in their body of work include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Myeloid Leukemia Treatments, Immunodeficiency and Autoimmune Disorders, Viral-associated cancers and disorders, and Advanced Breast Cancer Therapies.

The scientist has published extensively in a variety of journals, with frequent contributions to the following venues:

  • Blood
  • Hematological Oncology
  • Journal of Clinical Oncology
  • Blood Advances
  • Leukemia & lymphoma/Leukemia and lymphoma

Notable recent papers authored or co-authored by John F. Seymour include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee (2022, Blood)
  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial (2021, Journal of Clinical Oncology)
  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2020, Annals of Oncology)
  • Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study (2020, Journal of Clinical Oncology)
  • Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia (2023, New England Journal of Medicine)

Collaborations have been frequent with several researchers, including:

  • Constantine S. Tam
  • Chan Y. Cheah
  • Piers Blombery
  • Arnon P. Kater
  • Mary Ann Anderson

Best Publications

  • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

    Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler

  • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini

  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

    Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;A.M. Fink

  • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

    Hervé Dombret;John F. Seymour;Aleksandra Butrym;Agnieszka Wierzbowska

  • Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

    Pierre Fenaux;Ghulam J. Mufti;Eva Hellström-Lindberg;Valeria Santini

  • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

    John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

  • Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

  • Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Lauren E. Abrey;Tracy T. Batchelor;Andrés J.M. Ferreri;Mary Gospodarowicz

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Pulmonary alveolar proteinosis: progress in the first 44 years.

    John F. Seymour;Jeffrey J. Presneill

  • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer

  • Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

    Kirsten Fischer;Jasmin Bahlo;Anna Maria Fink;Valentin Goede

  • Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Matthew S. Davids;Andrew W. Roberts;Andrew W. Roberts;John F. Seymour;John F. Seymour;John M. Pagel

  • Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

    Robert Marcus;Andrew Davies;Kiyoshi Ando;Wolfram Klapper

  • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

    Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

Frequent Co-Authors

Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Constantine S. Tam
Constantine S. Tam University of Melbourne
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
H. Miles Prince
H. Miles Prince Peter MacCallum Cancer Centre
Andrew Grigg
Andrew Grigg Austin Hospital
Rodney J. Hicks
Rodney J. Hicks Peter MacCallum Cancer Centre
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
David C. S. Huang
David C. S. Huang Walter and Eliza Hall Institute of Medical Research
Pierre Fenaux
Pierre Fenaux Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA often opens up a diverse range of career pathways, many of which can also be pursued through online education. For those looking to enter healthcare quickly or work behind the scenes, earning a medical billing and coding certification online can lead to rewarding roles in healthcare administration with flexible work options.

Aspiring nurses have plenty of choices too. There are online nurse practitioner programs for those who want to advance their clinical skills and gain independent practice rights. If affordability is a key consideration, students can find cheap online nursing programs that provide quality education without a high price tag.

For experienced nurses aiming for leadership, teaching, or research roles, pursuing phd nursing programs online allows for greater flexibility while balancing work and study. These online pathways make advanced healthcare education more accessible, helping support the growing demand for skilled professionals across the medical field.

Best Scientists Citing John F. Seymour

Trending Scientists

Recently Published Articles